Safety and efficacy of nebulized lignocaine in patients with cancer and breathlessness.
Although anecdotal reports suggest nebulized lignocaine may help breathlessness in patients with cancer this has not been examined formally. We report a pilot study comparing nebulized lignocaine 100 mg and 200 mg with saline in six patients with cancer who were breathless at rest. Nebulized lignocaine was well tolerated apart from mild bronchoconstriction in two patients after the 200 mg dose and the unpleasant taste; serum concentrations were below levels at which toxicity has been reported. The effort of breathing (measured on a visual analogue scale) did not differ between treatments, whereas the distress of breathing was less after saline than after either dose of lignocaine. These findings do not support the reported benefits of nebulized lignocaine.
Wilcock
A
A
City Hospital, Nottingham.
Corcoran
R
R
Tattersfield
A E
AE
D000281:Administration, Intranasal; D000368:Aged; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D009330:Nebulizers and Vaporizers; D009369:Neoplasms / Q000150:complications*; D010166:Palliative Care; D012120:Respiration Disorders / Q000188:drug therapy*; D013727:Terminal Care
D008012:Lidocaine